SIX · ROP.SW
Roche Holding AG
CHF 402.50+CHF 0.80 (+0.2%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.84% below the high.
Loading market information…
SIX · SOON.SW · CHF
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 02:51 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CHF. Historical prices are not a forecast.
Sonova Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.98% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Sonova Holding AG’s forward annual dividend is CHF 4.70 per share, paid annual. The forward yield is 1.66% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Sonova Holding AG’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of CHF 4.56. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sonova Holding AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Headquartered in Stäfa, Switzerland, Sonova Holding AG is a leading provider of innovative hearing care solutions for both adults and children. The company's operations are divided into two primary segments: Hearing Instruments and Cochlear Implants. Sonova's extensive offerings include advanced wireless communication devices, rechargeable hearing aids, wireless headsets, speech-enhanced hearables, premium audiophile headphones, microphones, and wireless transmission systems, alongside comprehensive audiological care services. Its renowned hearing aid brands comprise Phonak, Unitron, and Hansaton, while Advanced Bionics is its flagship for cochlear implants. For consumer audio, Sonova offers products under the Sennheiser brand. The company delivers its audiological care through a vast network of around 3,600 clinics and stores operating under various regional names such as AudioNova, Audium, and Boots Hearingcare, among others. Additionally, its products are distributed via independent partners. Sonova boasts a significant international presence, serving markets across the United States, Europe, the Middle East, Africa, and the Asia Pacific. Founded in 1947, the company was formerly known as Phonak Holding AG before officially changing its name to Sonova Holding AG in August 2007.
Latest available per-share figures in CHF. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:06 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2024 | Nov 21, 2023 | CHF 4.34+4.33% vs estimate | CHF 1.75B-0.25% vs estimate |
|---|
| Q4 2023 | May 16, 2023 | CHF 5.83-0.34% vs estimate | CHF 1.89B-2.52% vs estimate |
|---|
| Q2 2023 | Nov 14, 2022 | CHF 4.90+2.51% vs estimate | CHF 1.85B+0.01% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 402.50+CHF 0.80 (+0.2%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.84% below the high.
CHF 134.08+CHF 1.78 (+1.35%)
Novartis AG’s quoted price sits in the upper half of its reported 52-week range, 0.73% below the high.
$105.79+$1.22 (+1.17%)
Abbott Laboratories’s quoted price sits in the lower half of its reported 52-week range, 19.87% below the high.
$97.03-$0.09 (-0.09%)
Medtronic Plc’s quoted price sits in the upper half of its reported 52-week range, 8.75% below the high.
CHF 646.20+CHF 5.40 (+0.84%)
Lonza Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.58% below the high.
€24.34+€0.06 (+0.25%)
Koninklijke Philips N.V.’s quoted price sits in the upper half of its reported 52-week range, 12.13% below the high.
DKK 367.00+DKK 1.00 (+0.27%)
Demant A/S’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
A$143.64+A$1.44 (+1.01%)
Cochlear Limited’s quoted price sits in the lower half of its reported 52-week range, 50.67% below the high.
